Eli Lilly and Company (NYSE:LLY) Shares Sold by Amplius Wealth Advisors LLC

Amplius Wealth Advisors LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,472 shares of the company’s stock after selling 27 shares during the quarter. Amplius Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,333,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Lynx Investment Advisory acquired a new position in Eli Lilly and Company during the second quarter worth $32,000. Core Wealth Advisors Inc. increased its position in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the period. Activest Wealth Management acquired a new stake in Eli Lilly and Company during the 1st quarter worth $39,000. Tidemark LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $29,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $40,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on LLY shares. Argus lifted their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price objective for the company from $725.00 to $1,025.00 in a research note on Monday, August 12th. Jefferies Financial Group lifted their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Finally, BMO Capital Markets increased their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $956.88.

Eli Lilly and Company Price Performance

NYSE LLY traded up $2.00 on Wednesday, reaching $951.97. The company’s stock had a trading volume of 2,496,047 shares, compared to its average volume of 3,101,510. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $967.00. The stock has a market cap of $904.76 billion, a PE ratio of 140.20, a PEG ratio of 1.81 and a beta of 0.41. The firm’s 50 day moving average is $883.39 and its two-hundred day moving average is $811.11. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.55%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of the business’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the transaction, the insider now owns 98,556,247 shares of the company’s stock, valued at approximately $79,752,700,634.87. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,214,704 shares of company stock worth $1,066,841,316. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.